Literature DB >> 8275482

Rapid tumor imaging by active background reduction using biotin-bearing liposomes and avidin.

I Ogihara-Umeda1, T Sasaki, H Toyama, K Oda, M Senda, H Nishigori.   

Abstract

Tumor imaging with labeled liposomes is slow; although they reach the tumor quickly, their blood clearance is slow, and the high blood background hinders early imaging. We have developed a rapid tumor imaging technique based on the active removal of liposomes from the circulation by using the avidin-biotin system. 67Ga- or 111In-labeled liposomes with biotin molecules bound on the surface were administered to mice bearing sarcoma 180, and avidin was administered 2 h later. The strong affinity between biotin and avidin initiated the aggregation of liposomes, resulting in their rapid removal from the circulation by the reticuloendothelial system, and the blood level of radioactivity was dramatically reduced without any change of the tumor level. Consequently, the tumor:blood ratio reached 14-18 only 2.5 h after liposome injection. Increased accumulation in the liver was also observed. By this method, an acceptable tumor image could be obtained no more than 2 h after administration of labeled liposomes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8275482

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  4 in total

1.  Creating functional vesicle assemblies from vesicles and nanoparticles.

Authors:  Robert J Mart; Kwan Ping Liem; Simon J Webb
Journal:  Pharm Res       Date:  2009-04-23       Impact factor: 4.200

2.  Distribution of neocarzinostatin conjugated to biotinylated chimeric monoclonal antibody Fab fragments after administration of avidin.

Authors:  E Otsuji; T Yamaguchi; H Matsumura; K Yamamoto; H Tsuruta; Y Yata; H Nishi; K Okamoto; K Kitamura; T Takahashi
Journal:  Br J Cancer       Date:  1996-08       Impact factor: 7.640

3.  Decreased renal accumulation of biotinylated chimeric monoclonal antibody-neocarzinostatin conjugate after administration of avidin.

Authors:  E Otsuji; T Yamaguchi; K Yamamoto; H Matsumura; H Tsuruta; Y Yata; H Nishi; K Okamoto; K Kitamura; T Takahashi
Journal:  Jpn J Cancer Res       Date:  1997-02

4.  Galactosylated streptavidin for improved clearance of biotinylated intact and F(ab')2 fragments of an anti-tumour antibody.

Authors:  D Marshall; R B Pedley; R G Melton; J A Boden; R Boden; R H Begent
Journal:  Br J Cancer       Date:  1995-01       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.